• Arcutis Biotherapeutics director Howard G. Welgus sold 4,730 shares at USD 26.91 on July 15, 2026.
• He exercised stock options for 4,096 shares at USD 6.52 to USD 8.63 on the same day.
• Directly held common stock ended at 37,109 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-048641), on July 17, 2026, and is solely responsible for the information contained therein.